Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders - Takeaways - MDSpire

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

  • By

  • Edward Koo

  • Sarah Albert

  • Benjamin Patrick

  • Meriem Henia

  • Yona Rhiwi

  • Christopher McCudden

  • Victor Jimenez Zepeda

  • Irwindeep Sandhu

  • Michael Chu

  • Hira Mian

  • Alissa Visram

  • March 26, 2026

  • 0 min

Share

  • 1

    Multiple myeloma (MM) often follows asymptomatic precursor states like MGUS and SMM, with MGUS prevalence reaching 5% in those over 50.

  • 2

    Patients with a prior history of precursor plasma cell disorders (pPCD) experience significantly lower rates of myeloma-related complications at diagnosis.

  • 3

    The median time from precursor diagnosis to MM diagnosis is longer for MGUS patients compared to those with SMM or solitary plasmacytoma.

  • 4

    pPCD patients have a 71% reduction in odds of presenting with severe myeloma-defining events at diagnosis compared to those without prior PCD.

  • 5

    Structured clinical follow-up for pPCD patients may lead to earlier detection of MM and reduced incidence of complications like anemia and bone lesions.

Original Source(s)

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

  • by Edward Koo, Sarah Albert, Benjamin Patrick, Meriem Henia, Yona Rhiwi, Christopher McCudden, Victor Jimenez Zepeda, Irwindeep Sandhu, Michael Chu, Hira Mian, Alissa Visram

  • March 26, 2026

Related Content

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma